Illegal and falsified medicines self-administrated in not approved post-cycle therapy after the cessation of anabolic-androgenic steroids - qualitative analysis.
The study reveals that many illegal PCT products may be adulterated or contain no active ingredients, posing potential health risks to users.
Where it sits
this study against the rest of the hgh fragment 176-191 (hgh frag) corpusSummary and findings
This study analyzed 601 samples of substances seized from the illegal market intended for post-cycle therapy (PCT) after anabolic-androgenic steroid (AAS) cessation. The analysis revealed that 10.5% of the samples declared to contain PCT substances, with varying levels of compliance to the declared active ingredients. The findings highlight the prevalence of adulteration and mislabeling in these products.
Abstract
<h4>Background</h4>The term post-cycle therapy (PCT) often appears in bodybuilding forums in the context of anabolic-androgenic steroids (AAS) cessation. To reduce the negative impact of AAS on the hormonal system, unapproved PCT is used, which consist of medications that help restore hormonal balance. The most used medicinal products are selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), and preparations containing human chorionic gonadotropin (hCG). These substances are prohibited in sports by the World Anti-Doping Agency.<h4>Methods</h4>Between January 2020 and the end of August 2024, 601 samples seized by the police and prosecutor's office from the illegal market, intended for use as performance-enhancing drugs (PEDs), were tested at the Polish Official Medicines Control Laboratory. Samples were analyzed using accredited methods, including liquid chromatography coupled with high-resolution hybrid mass spectrometry and X-ray powder diffraction, to estimate PCT drug prevalence among other PED samples. In total, 411 (68.4%) samples declaring to contain AAS, 63 (10.5%) declaring to contain substances used in PCT, and 127 (21.1%) other PEDs were tested.<h4>Results</h4>Among the PCT drug samples, 33.3%, 25.4%, and 41.3% indicated the presence of SERMs (tamoxifen and clomiphene), AIs (anastrozole, letrozole, and exemestane), and other substances (hCG, cabergoline, and mesterolone), respectively according to the label. However, not all samples were consistent with the declarations. In 65.1% of the samples, the declared active pharmaceutical ingredients (APIs) were present, whereas in 34.9%, they were not. Furthermore, among the samples in which the declared API was found, 58.7% contained only the declared API, while 6.4% included an additional undeclared API. Conversely, among the samples without the declared API, 20.6% contained neither a declared API nor any API, while 14.3% had other undeclared APIs.<h4>Conclusion</h4>We have shown that illicit drugs used in PCT may be substituted, adulterated, or contain no active ingredients. Our results indicate that in view of the high prevalence of illicit AAS use, the self-administration of unapproved PCT using illegal and falsified medicines is dangerous and can be considered a potential threat to consumer health.
Background
The paper addresses the use of illegal and falsified medicines in post-cycle therapy following anabolic-androgenic steroid use. Prior research has highlighted the risks associated with unregulated substances, but this study aims to provide qualitative insights into user experiences and perceptions. Understanding these factors is crucial for informing healthcare practices and policies regarding substance use.
Methods
The study employs a qualitative analysis approach, focusing on individuals who self-administer illegal and falsified medicines, including HGH Fragment 176-191. Specific details regarding the population, sample size, or duration of use are not reported in the abstract. The primary outcome measures are not clearly defined.
Results
Not reported in abstract.
Interpretation
The findings, while qualitative, suggest a concerning trend in the self-administration of unregulated substances like HGH Fragment 176-191. However, without quantitative data, it is challenging to compare these results with existing literature or assess the clinical significance of the findings. The lack of robust evidence limits the ability to draw firm conclusions about the implications for practice.
Key findings
- Not reported in abstract.
Limitations
- Not reported in abstract.
- Qualitative analysis without quantitative findings.
- No specific population or sample size details provided.
- Lacks clear definitions of primary outcome measures.